# Effect of alpha‐lipoic acid and myoinositol on endometrial inflammation in women with unexplained recurrent pregnancy loss

## TL;DR

This study shows that a combination of alpha-lipoic acid and myo-inositol can reduce inflammation in women with unexplained recurrent pregnancy loss.

## Contribution

The study demonstrates that ALA and Myo can modulate inflammatory markers in uRPL patients.

## Key findings

- uRPL women had higher serum and endometrial HMGB-1 levels compared to controls.
- ALA and Myo treatment significantly reduced NLRP-3 and HMGB-1 levels in uRPL women.
- Post-treatment levels in uRPL women became similar to those in controls.

## Abstract

The aim of this study was to investigate the effect of oral administration of a combination of alpha- lipoic acid (ALA) and myo-inositol (Myo) on serum and endometrial inflammation of women with unexplained recurrent pregnancy loss (uRPL).

Serum and endometrial levels of Nacht leucine-rich-repeat protein-3 (NLRP-3) and High Mobility Group Box 1 (HMGB-1) were analyzed by ELISA in women with unexplained Recurrent Pregnancy Loss (uRPL) (n = 31) and in control women who had had at least one uncomplicated pregnancy at term (n = 10) before and after daily oral administration of a commercial combination of ALA and Myo.

uRPL women had higher serum levels (p < 0.01) and endometrial content (p < 0.0001) of HMGB-1 than controls while no difference was observed regarding NALP3. Oral administration of ALA and Myo for three months significantly decreased pre-treatment serum levels of NLRP-3 (p < 0.0001) and HMGB-1 (p < 0.0001), as well as endometrial content of NLRP-3 (p < 0.001) and HMGB-1 (p < 0.0001) in uRPL women, similar to those found in controls.

Women with uRPL have increased systemic and endometrial inflammation than controls. Oral administration of ALA and Myo could modulate serum and endometrial levels of NLRP-3 and HMGB-1 in uRPL women.